2 weeks Ago By ABMN Staff
Sonnet BioTherapeutics Holdings, Inc. ( NASDAQ:SONN – Get Free Report ) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 34,700 shares, a drop of 21.
8% from the August 31st total of 44,400 shares. Based on an average daily volume of 133,800 shares, the short-interest ratio is presently 0.3 days.
Currently, 0.7% of the company’s stock are sold short. Analyst Ratings Changes Separately, Chardan Capital reiterated a “buy” rating and issued a $30.
00 target price on shares of Sonnet BioTherapeutics in a report on Friday, August 23rd. Check Out Our Latest Analysis on SONN Institutional Investors Weigh In On Sonnet BioTherapeutics Sonnet BioTherapeutics Price Performance Shares of SONN traded down $0.02 during trading hours on Friday, reaching $0.
71. The stock had a trading volume of 118,912 shares, compared to its average volume of 93,287. Sonnet BioTherapeutics has a 12 month low of $0.
62 and a 12 month high of $2.97. The firm has a 50-day simple moving average of $0.
81 and a 200 day simple moving average of $1.33. Sonnet BioTherapeutics ( NASDAQ:SONN – Get Free Report ) last released its quarterly earnings results on Wednesday, August 14th.
The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.
06. Sonnet BioTherapeutics had a negative return on equity of 398.45% and a negative net margin of 11,187.
19%. Sell-side analysts anticipate that Sonnet BioTherapeutics will post -1.61 earnings per share for the current fiscal year.
About Sonnet BioTherapeutics ( Get Free Report ) Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Recommended Stories Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
